NO992902L - Diagnostiske markoerer for humane sykdommer - Google Patents

Diagnostiske markoerer for humane sykdommer

Info

Publication number
NO992902L
NO992902L NO992902A NO992902A NO992902L NO 992902 L NO992902 L NO 992902L NO 992902 A NO992902 A NO 992902A NO 992902 A NO992902 A NO 992902A NO 992902 L NO992902 L NO 992902L
Authority
NO
Norway
Prior art keywords
diseases
diagnostic markers
peptides
human diseases
derivatives
Prior art date
Application number
NO992902A
Other languages
English (en)
Other versions
NO992902D0 (no
Inventor
Michelle R Shanahan
Albert J Venturini
John L Daiss
Alan E Friedman
Original Assignee
Ortho Clinical Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Clinical Diagnostics Inc filed Critical Ortho Clinical Diagnostics Inc
Publication of NO992902D0 publication Critical patent/NO992902D0/no
Publication of NO992902L publication Critical patent/NO992902L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732—Casein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Foreliggende vedrører i store trekk humane sykdommer inklusive, men er ikke begren- set til, metabolske og ernæringsmessige sykdommer, magetarmsykdommer, sentralner- vesystemsykdommer og autoimmune eller redusert immunitetssykdommer. Den foreliggende oppfinnelse vedrører mer spesifikt til diagnostiske markører som om- fatter isolerte peptider opprinnelig funnet i humant vev og kroppsvæsker og derivater derav. Disse peptidene har blitt funnet å konsekvent utvise opiatlignende aktivitet og/eller er derivater av peptider som utviser opiatlignende aktivitet.
NO992902A 1998-06-15 1999-06-14 Diagnostiske markoerer for humane sykdommer NO992902L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8923798P 1998-06-15 1998-06-15
US8923898P 1998-06-15 1998-06-15
US31770299A 1999-05-24 1999-05-24

Publications (2)

Publication Number Publication Date
NO992902D0 NO992902D0 (no) 1999-06-14
NO992902L true NO992902L (no) 1999-12-16

Family

ID=27376259

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992902A NO992902L (no) 1998-06-15 1999-06-14 Diagnostiske markoerer for humane sykdommer

Country Status (6)

Country Link
EP (1) EP0969015A3 (no)
JP (1) JP2000221191A (no)
KR (1) KR20000006190A (no)
CN (1) CN1247984A (no)
CA (1) CA2273683A1 (no)
NO (1) NO992902L (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO318426B1 (no) 2001-10-02 2005-04-18 Neurozym Biotech As Et materiale for a senke konsentrasjonen av patogene tarmpeptider
SE0300586L (sv) 2003-03-04 2004-09-05 Forskarpatent I Syd Ab Diagnos av autism
GB0504096D0 (en) * 2005-02-28 2005-04-06 Tipogen As Method
US9547013B2 (en) * 2010-04-29 2017-01-17 Wisconsin Alumni Research Foundation Molecule biomarkers of autism
WO2013047082A1 (ja) * 2011-09-29 2013-04-04 天野エンザイム株式会社 外因性オピオイドペプチド分解酵素剤
KR102191787B1 (ko) * 2015-10-14 2020-12-17 삼육대학교산학협력단 Ａｄｈｄ 검출용 바이오마커
RU2651038C1 (ru) * 2017-07-21 2018-04-18 Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью Способ выявления нарушений у детей иммунологической реактивности в условиях избыточной экспозиции стронцием
US11491144B2 (en) 2018-03-30 2022-11-08 The Florida State University Research Foundation, Incorporated Methods of treating fragile X mental retardation syndrome
KR102341323B1 (ko) 2020-07-07 2021-12-21 한국원자력의학원 미세플라스틱 노출에 의해 유도되는 뇌질환 예후 예측용 바이오마커 조성물 및 이를 이용한 예후 예측방법
KR102639856B1 (ko) 2020-10-14 2024-02-23 한국원자력의학원 미세플라스틱 노출에 의해 유도되는 뇌질환 예후 예측용 바이오마커 조성물 및 이를 이용한 예후 예측방법

Also Published As

Publication number Publication date
EP0969015A3 (en) 2002-10-09
CA2273683A1 (en) 1999-12-15
CN1247984A (zh) 2000-03-22
JP2000221191A (ja) 2000-08-11
NO992902D0 (no) 1999-06-14
KR20000006190A (ko) 2000-01-25
EP0969015A2 (en) 2000-01-05

Similar Documents

Publication Publication Date Title
AU3368497A (en) Human dnase i hyperactive variants
CA2274596A1 (en) Compositions and methods for enhancing intestinal function
GR3031488T3 (en) Laminin chains: diagnostic and therapeutic use
NO992902L (no) Diagnostiske markoerer for humane sykdommer
DE69427650T2 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
HUP0101317A2 (hu) Módosított VIII-as faktor
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
EP1978362A3 (en) Cross beta structure comprising amyloid binding proteins and methods for detection of the cross beta structure, for modulating cross beta structures fibril formation and for modulating cross beta structure-mediated toxicity
HUP0102479A2 (hu) Neisseria meningitidis-ből származó BASBO29-polinukleotid(ok) és polipeptidek
DE69711078T2 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
AU9363398A (en) Hepatitis c receptor protein cd81
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
DE60024997D1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
HK1061209A1 (en) Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
ATE230263T1 (de) At1 rezeptor antagonist zur anregung von apoptosis
WO1999055859A3 (en) Cd40-interacting and traf-interacting proteins
ATE512983T1 (de) Rezeptor für das tgr3-like protein
DK0811068T3 (da) Humane DNase I varianter
WO2002070557A3 (en) Nuclear hormone receptor ligand binding domain
WO2004005346A8 (en) Human nuclear hormone receptor
WO2003106666A3 (en) VARIANTS OF PROTEIN C WITH MODIFIED PROPERTIES
WO2001000655A3 (en) Therapeutic peptides derived from subsequences of bpi
GB0216727D0 (en) Genes
WO2004003010A3 (en) Nuclear hormone receptor ligano-binding domain containing protein

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application